|
24 Companies |
|
9 Products |
|
9 Products |
|
6 Mechanisms of Action |
|
50 Trials |
|
3648 News |
|
| «12...48495051525354555657585960» |
- | Somavert (pegvisomant) / Pfizer
Phase classification: Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan (clinicaltrials.gov) - Oct 28, 2014
P4, N=1000, Enrolling by invitation, Sponsor: Pfizer
Phase classification: P=N/A --> P4
- clomifene citrate / Generic mfg.
New P2 trial: Clomiphene Citrate for Treatment of Acromegaly (clinicaltrials.gov) - Oct 24, 2014
P2, N=16, Completed, Sponsor: Felipe Henning Gaia Duarte
- |||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Oct 23, 2014
P3, N=190, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P=N/A --> P4 Trial primary completion date: Dec 2015 --> Jan 2013
- Enrollment open, Trial initiation date: Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly (clinicaltrials.gov) - Sep 28, 2014
P4, N=24, Recruiting, Sponsor: Medical University of Vienna
Trial primary completion date: Dec 2015 --> Jan 2013 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- ||| Trial completion, Trial primary completion date: Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=138, Completed, Sponsor: University Hospital Tuebingen
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2010 --> Apr 2011
- veldoreotide (DG3173) / Xeris Biopharma
New P2 trial: Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. (clinicaltrials.gov) - Sep 10, 2014
P2, N=20, Completed, Sponsor: Aspireo Pharmaceuticals Limited
- | Somavert (pegvisomant) / Pfizer
Phase classification: Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=1000, Enrolling by invitation, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Apr 2010 --> Apr 2011 Phase classification: P4 --> P=N/A
- ||| Clinical: SAGIT Pilot Study: SAGIT for Classification of Patients With Acromegaly in Clinical Practice (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=71, Completed, Sponsor: Ipsen
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Enrollment open: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=34, Recruiting, Sponsor: Ipsen
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, HEOR: Study in Polish Acromegalic Patients Treated With Somatuline Autogel (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=150, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Phase classification: ACCESS: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=0, Available, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed Phase classification: P4 --> P=N/A
- veldoreotide (DG3173) / Xeris Biopharma
New P2 trial: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (clinicaltrials.gov) - Aug 15, 2014
P2, N=20, Active, not recruiting, Sponsor: Aspireo Pharmaceuticals Limited
- Signifor LAR (pasireotide long acting release) / Recordati
Phase classification: ACCESS: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (clinicaltrials.gov) - Aug 12, 2014
P4, N=0, Available, Sponsor: Novartis Pharmaceuticals
Phase classification: P4 --> P=N/A Phase classification: P=N/A --> P4
- | Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, octreotide acetate / Generic mfg.
New P4 trial: Evaluation of a treatment regimen for acromegaly (EUDRACT) - Aug 7, 2014
P4, N=100, Ongoing, Sponsor:
- octreotide acetate solution for injection / Generic mfg.
Trial completion, Surgery: SAPORO: Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=89, Completed, Sponsor: University Hospital, Rouen
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed
- ||| Trial completion: ACRO-POLIS: Description of Sign-and-symptom Associations at Acromegaly Diagnosis. (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=648, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Trial completion: Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease (clinicaltrials.gov) - Jul 30, 2014
P1, N=85, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Somavert (pegvisomant) / Pfizer
Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=51, Recruiting, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2017
- |||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (clinicaltrials.gov) - Jul 17, 2014
P4, N=133, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2017 Not yet recruiting --> Recruiting
- Signifor LAR (pasireotide long acting release) / Recordati
Phase classification: ACCESS: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=0, Available, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Phase classification: P4 --> P=N/A
- | Enrollment open: Phase II Study With ITF2984 in Acromegalic Patients (clinicaltrials.gov) - Jul 14, 2014
P2, N=40, Recruiting, Sponsor: Italfarmaco
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- | Signifor LAR (pasireotide long acting release) / Recordati
Enrollment closed: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (clinicaltrials.gov) - Jul 8, 2014
P2, N=33, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial primary completion date: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2019 --> Jul 2019
- Enrollment open: Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=50, Recruiting, Sponsor: University Hospital, Ghent
Trial primary completion date: Feb 2019 --> Jul 2019 Not yet recruiting --> Recruiting
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker, Trial initiation date: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Apr 28, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> May 2014
- Enrollment change, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Initiation date: Mar 2014 --> May 2014 N=300 --> 200
- Enrollment closed, Surgery: Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
N=300 --> 200 Enrolling by invitation --> Active, not recruiting
- New P4 trial: Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly (clinicaltrials.gov) - Apr 14, 2014
P4, N=24, Not yet recruiting, Sponsor: Medical University of Vienna
- | New P2 trial: Phase II Study With ITF2984 in Acromegalic Patients (clinicaltrials.gov) - Apr 8, 2014
P2, N=40, Not yet recruiting, Sponsor: Italfarmaco
- | Mycapssa (octreotide) / Chiesi
Enrollment closed: Efficacy and Safety of Octreotide (MYCAPSSA (clinicaltrials.gov) - Mar 24, 2014
P3, N=150, Active, not recruiting, Sponsor: Chiasma, Inc.
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=79, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
- | Signifor (pasireotide) / Recordati
Trial completion: An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly (clinicaltrials.gov) - Mar 10, 2014
P2, N=30, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Somavert (pegvisomant) / Pfizer
Trial completion: A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly (clinicaltrials.gov) - Feb 22, 2014
P4, N=100, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| Somavert (pegvisomant) / Pfizer
Trial completion: Pegvisomant And Sandostatin LAR Combination Study (clinicaltrials.gov) - Feb 22, 2014
P4, N=75, Completed, Sponsor: Pfizer
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||| Signifor LAR (pasireotide long acting release) / Recordati
New P4 trial: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (clinicaltrials.gov) - Feb 10, 2014
P4, N=133, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Biomarker: TAPAS: Predictive Factors Study (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=34, Not yet recruiting, Sponsor: Ipsen
- ||| Clinical: ACROSCREEN: Programme of Acromegaly Screening in Patients With Associated Somatic Disorders (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=2000, Recruiting, Sponsor: Ipsen
- Enrollment closed: Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors (clinicaltrials.gov) - Dec 1, 2013
P=N/A, N=44, Active, not recruiting, Sponsor: Emory University
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Signifor LAR (pasireotide long acting release) / Recordati
New P4 trial: ACCESS: An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (clinicaltrials.gov) - Nov 25, 2013
P4, N=0, Available, Sponsor: Novartis Pharmaceuticals
- ||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Nov 12, 2013
P3, N=190, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: LEAD: Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (clinicaltrials.gov) - Oct 6, 2013
P4, N=124, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | octreotide implant (VP-003) / Endo
Trial termination: Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly (clinicaltrials.gov) - Sep 19, 2013
P3, N=169, Terminated, Sponsor: Endo Pharmaceuticals
Active, not recruiting --> Completed Completed --> Terminated
- | octreotide implant (VP-003) / Endo
Enrollment change: Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly (clinicaltrials.gov) - Sep 16, 2013
P3, N=169, Terminated, Sponsor: Endo Pharmaceuticals
Completed --> Terminated N=140 --> 169
- octreotide implant (VP-003) / Endo
Enrollment change: Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly (clinicaltrials.gov) - Sep 8, 2013
P3, N=12, Terminated, Sponsor: Endo Pharmaceuticals
N=140 --> 169 N=18 --> 12
- |||| Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Aug 26, 2013
P4, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 12 Not yet recruiting --> Recruiting
- Enrollment open: Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=80, Recruiting, Sponsor: TC Erciyes University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Epidemiology of Acromegaly in Denmark 1991-2010 (clinicaltrials.gov) - Jul 4, 2013
P=N/A, N=500, Recruiting, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects (clinicaltrials.gov) - Jul 4, 2013
P=N/A, N=30, Recruiting, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open: Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly (clinicaltrials.gov) - Jul 1, 2013
P=N/A, N=52, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment (clinicaltrials.gov) - Jul 1, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting